NCT04496089View on ClinicalTrials.gov

Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

October 27, 2020

Study Completion Date

April 6, 2021

Conditions
Carcinoma, Renal CellClear Cell Renal Cell Carcinoma
Interventions
DIAGNOSTIC_TEST

89Zr-girentuximab

A single dose of 37 MBq (±10%) is administered. The dose per dose is equivalent to girentuximab 10 mg (±10%).

Trial Locations (1)

236-0004

Yokohama City University Hospital, Yokohama

All Listed Sponsors
lead

Telix Pharmaceuticals (Innovations) Pty Limited

INDUSTRY

NCT04496089 - Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC | Biotech Hunter | Biotech Hunter